Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

NCT02446912 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Active Systemic Lupus Erythematosus

Interventions

BIOLOGICAL: Anifrolumab
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]